A study led by researchers at Cedars-Sinai and NeuroVision Imaging LLC provides the scientific basis for using noninvasive eye imaging to detect the pathological hallmarks of Alzheimer’s. The experimental technology, developed by Cedars-Sinai and NeuroVision, scans the retina using techniques that can identify beta-amyloid protein deposits that mirror those in the brain.
ProMIS Neurosciences announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach.”
Danish drugmaker Lundbeck is betting that shark antibodies may offer a new way of getting drugs into the brain to fight Alzheimer’s and other diseases, after successful early research with privately owned U.S. biotech firm Ossianix.
Eli Lilly is looking to begin 2017 with a series of organizational changes that includes changes in some leadership roles.
2016 was not a banner year for M&A in the biopharma industry compared to 2014 and 2015. BioPharmaDIVE looks at seven potential acquisition targets for 2017.
The U.S. Senate voted overwhelmingly to support sweeping legislation that will reshape the way the Food and Drug Administration approves new medicines.
In yet another buy in its string of acquisitions, Dublin-based Allergan announced it was acquiring San Francisco-based Tobira Therapeutics.
San Diego-based Arena Pharmaceuticals announced that it had created an independent, privately held drug discovery incubator called Beacon Discovery.
Japan’s Eisai Co. said the U.S. FDA had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer’s disease.
TauRx Pharmaceuticals’ experimental Alzheimer’s drug LMTX failed to improve cognitive and functional skills in patients with mild to moderate Alzheimer’s disease.